Other
Outcome
0
Pipeline Programs↗
43
Active Trials↗
28
Companies Involved↗
Outcome is an early-stage landscape with 0 programs across 28 companies. The most active players are AstraZeneca, Bayer, Sanofi.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
196
clinical trials
Completed93 · 47%
Unknown status35 · 18%
Recruiting19 · 10%
Terminated13 · 7%
Active, not recruiting12 · 6%
Withdrawn11 · 6%
Other13 · 7%
Clinical Trials
Trial Activity
196 trials
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
Recruiting·—·Phase 2·NCT03089554·93 enrolled
Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
Recruiting·—·Phase 3·NCT06507059·40 enrolled
Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT06528028·140 enrolled
Effect of CoQ10 on the Outcome of MAFLD Patients
Recruiting·—·Phase 2·NCT05984745·60 enrolled
Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics
Recruiting·—·Phase 1·NCT07298057·42 enrolled
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Recruiting·—·N/A·NCT06567418·10,000 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)